HK Stock Market Move | RIMAG GROUP (02522) surged over 18% with AI-enabled medical imaging diagnosis. Institutions predict that the company is expected to enter the Hong Kong Stock Connect.

RIMAG GROUP (02522) rose more than 18%, as of the publication, it rose 18.17% to 39.35 Hong Kong dollars, with a turnover of 4.2821 million Hong Kong dollars. In terms of news, the Hang Seng Index will welcome a new round of review results on February 21, and this adjustment will officially take effect on March 10, with corresponding adjustments to the Hong Kong stock connect. According to CITIC SEC estimation, it is expected that 23 targets will enter the Hong Kong stock connect, including RIMAG GROUP. It is known that RIMAG GROUP's business covers the construction of medical imaging centers, medical imaging diagnostic services, imaging technology training, imaging informationization, and smart services in multiple sectors. Sinolink pointed out that with the development and progress of artificial intelligence technology, AI continues to make new progress in empowering the pharmaceutical and medical industries and promoting industry upgrades, with the application of artificial intelligence in the pharmaceutical and health fields expected to enter an accelerated development stage. In terms of investment in pharmaceutical AI, it is recommended to focus on areas such as medical equipment and diagnostic imaging. It is worth mentioning that in November last year, the National Medical Insurance Administration included artificial intelligence-assisted technology in the medical insurance project establishment guidelines, setting up "artificial intelligence-assisted" extension items in radiographic examinations, ultrasound examinations, and rehabilitation projects, supporting relatively mature artificial intelligence-assisted technologies to enter clinical applications while ensuring no additional burden on patients. Earlier, the National Medical Insurance Administration issued the "Radiographic Examination Price Project Establishment Guidelines (Trial)" to integrate existing radiographic examination projects, promote price rationality, emphasize support for AI-assisted diagnosis and cloud imaging technology, and promote the sharing and mutual recognition of examination results across regions and institutions.